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Abstract: Coronary heart disease is a global malady and it is the leading cause of death in the United States. Chronic stable angina is
the most common manifestation of coronary heart disease and it results from the imbalance between myocardial oxygen supply and
demand due to reduction in coronary blood flow. Therefore, in addition to lifestyle changes, commonly used pharmaceutical treatments
for angina (nitrates, β-blockers, Ca2+ channel blockers) are aimed at increasing blood flow or decreasing O2 demand. However, patients
may continue to experience symptoms of angina. Ranolazine is a relatively new drug with anti-anginal and anti-arrhythmic effects. Its
anti-anginal mechanism is not clearly understood but the general consensus is that ranolazine brings about its anti-anginal effects by
inhibiting the late Na+ current and the subsequent intracellular Ca2+ accumulation. Recent studies suggest other effects of ranolazine that
may explain its anti-anginal and anti-arrhythmic effects. Nonetheless, clinical trials have proven the efficacy of ranolazine in treating
chronic angina. It has been shown to be ineffective, however, in treating acute coronary syndrome patients. Ranolazine is a safe drug
with minimal side effects. It is metabolized mainly in the liver and cleared by the kidney. Therefore, caution must be taken in patients
with impaired hepatic or renal function. Due to its efficacy and safety, ranolazine was approved for the treatment of chronic angina by
the Food and Drug Administration (FDA) in 2006.
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Introduction

Cardiovascular diseases are the number one cause of
death globally. According to the World Health Organization, an estimated 17.3 million people died from
cardiovascular diseases in 2008, representing 30% of
all global deaths. Of these deaths, an estimated 7.3 million were due to coronary heart disease. Coronary
heart disease, along with stroke, is projected to remain
the single leading cause of death in the future. Chronic
stable angina is the most prevalent manifestation of
coronary artery disease (CAD) with an incidence of
320,000 cases in males and 180,000 cases in females
every year in the US.1 Stable angina is a clinical syndrome characterized by discomfort in the chest, jaw,
shoulder, back, or arms, typically elicited by exertion or
emotional stress and relieved by rest or nitroglycerin,2
and it is caused by an imbalance between myocardial
oxygen supply and myocardial oxygen consumption.
Management of chronic stable angina includes lifestyle
changes (eg, eating a heart-healthy diet, lowering cholesterol, getting regular exercise, cessation of smoking, and controlling diabetes and high blood pressure),
pharmacological treatment (β-blockers, Ca2+ channel
blockers, nitrates, and antiplatelet medications), and
revascularization procedures when indicated (percutaneous coronary intervention (PCI), coronary artery
bypass grafting).2 Despite the effectiveness of the current management strategies, episodes of angina may
still persist or even worsen3,4 and many patients cannot tolerate a combination of anti-anginal drugs due
to their many side effects. Therefore, a new treatment
that provides an alternative option for patients who
continue to suffer from symptoms of angina despite
using other anti-anginal drugs would be helpful.
Ranolazine is a relatively new drug for the treatment
of chronic angina that was approved by the Food and
Drug Administration (FDA) and has been in use in the
US since 2006.

Metabolism and Pharmacokinetic
Profile

Ranolazine is a racemic mixture, chemically described
as 1-piperazineacetamide, N-(2,6-dimethylphenyl)-4[2-hydroxy-3-(2-methoxyphenoxy)propyl], with the
empirical formula of C24H33N3O4.5 It contains two
enantiomeric forms (S-ranolazine and R-ranolazine).6
Ranolazine was initially manufactured in an immediate-release formulation but it was discontinued
2

due to the short elimination half life.7 Ranolazine
is currently manufactured by Gilead Sciences in an
extended (sustained)-release tablets of 500 mg and
1000 mg for clinical use and it is sold under the trade
name Ranexa®. It is extensively absorbed after oral
administration and it reaches peak plasma concentrations within 2–5 hours5,7 after a single dose where it
binds mainly to α-1 acid glycoprotein and weakly to
albumin. With a dose of 500–1000 mg given twice
daily, the peak to trough difference is only 1.6 fold.
Steady state is usually reached within 3 days of multiple dosing. The half-life of ranolazine at steady state
after oral administration is nearly 7 hours. Less than
5% of ranolazine is excreted unchanged by the kidney while the remainder is extensively and rapidly
metabolized mainly by CYP3A4 enzymes in the liver
and, to a lesser extent, by CYP2D6. Following a single oral dose of ranolazine, total elimination is 75%
in urine and 25% in feces. These pharmacokinetics
are not affected by age, gender, or food.5

Mechanism of Action

Although the precise mechanisms for the anti-anginal
effects of ranolazine are not well understood, several
pharmacological activities of ranolazine have been
described. Of these, two distinct mechanisms appear
to primarily promote its cardiac protection against
ischemic injury. These include its effect as a metabolic modulator and as a late Na+ current inhibitor.
Therefore, in this section we will summarize the findings of the many studies in which attempts were made
to elucidate the mechanism of action of ranolazine.
Table 1 summarizes some of the mechanisms of ranolazine that could be responsible for its anti-anginal
effects.

Ranolazine as a metabolic modulator

In general, drugs such as β-blockers, Ca2+ channel
blockers, and long acting nitrates exert their antianginal effects by causing hemodynamic changes
such as drop in blood pressure, heart rate, and/
or contractility which decreases cardiac work.8 On
the other hand, ranolazine as many trials showed,
does not have any clinically significant effect on
these hemodynamic parameters.9–14 Initially it was
reported that ranolazine was effective as an antianginal drug by acting as a metabolic modulator.15
For this mechanism, ranolazine was proposed to
Clinical Medicine Insights: Therapeutics 2013:5
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Table 1. A summary of the possible mechanisms of ranolazine as an anti-anginal drug.
Mechanism

Details

Notes

Effects on
metabolism

• Ranolazine increases the amount of active
dephosphorylated pyruvate dehydrogenase
• Ranolazine stimulates glucose oxidation
at the expense of fatty acid oxidation
• Ranolazine inhibits INaL and therefore
reduces Na+ overload during ischemia
• This reduces cytosolic Ca2+ overload that occurs by
activation of Na+/Ca2+ exchanger in the reverse mode
• This also reduces mitochondrial Ca2+ overload
• Ranolazine inhibits mitochondrial complex I
• Ranolazine reduces electron flow
to complex III during ischemia
• Ranolazine reduces mitochondrial
free radical generation
• Ranolazine modulates myofilament
cross-bridge kinetics and sensitivity to Ca2+
• Ranolazine improves diastolic function
at the cardiomyocyte level

• Concentration . 10 μM
(higher than used in clinical settings)
• This mechanism suggests an
intra-mitochondrial effect
• Ranolazine inhibits INaL with an
IC50 = 5.9 μM (within the clinical range)
• Ranolazine inhibits INaL possibly
by inhibiting the mechano-sensitivity
of Nav1.5
• Ranolazine is a weak inhibitor
of complex I in coupled mitochondria
• Ranolazine becomes more potent
as a complex I blocker in uncoupled
or broken mitochondria
• The effects on myofilaments are
achieved with concentrations
of ranolazine within the clinical range

Effects on late
Na+ current (INaL)

Effects on
mitochondrial
complex I
Effects on
myofilaments
Ca2+ sensitivity

stimulate glucose oxidation at the expense of fatty
acid oxidation. Under non-ischemic conditions, myocytes ATP requirement is met by both glucose and
fatty acid oxidation with the majority (about 90%)
coming from fatty acid oxidation.16 Fatty acid oxidation is more efficient, energy-wise, than glucose oxidation in ATP production. However as the supply of
O2 dwindles during ischemia, glucose becomes the
preferred substrate for ATP production because it is
more efficient oxygen-wise (for more details on this
topic refer to the review by Cheng et al16). Therefore,
by switching substrate utilization to glucose oxidation, ranolazine may provide a non-hemodynamic
mechanism for preserving cardiac myocytes during ischemia and reperfusion injury. It is not clear
how ranolazine promotes glucose oxidation, but in
perfused guinea pig hearts subjected to low-flow
ischemia it was shown that ranolazine increased the
amount of active dephosphorylated pyruvate dehydrogenase15 which is thought to play a key role in
determining the rate of carbohydrate utilization.17,18

Ranolazine as a late Na+ current inhibitor

The effect of ranolazine as a modulator of metabolism occurs at concentrations greater than 10 µM.
However, ranolazine exerts its effects as an antianginal drug at lower concentrations, ie, 2–6 µM.19
This implies that a mechanism other than promoting glucose oxidation is probably responsible for the
Clinical Medicine Insights: Therapeutics 2013:5

anti-anginal characteristics of ranolazine. Indeed, in
a comprehensive study19 it was shown that ranolazine produces several ion channel effects. Of particular interest was the inhibitory effect of ranolazine on
the late Na+ current (INaL) with an IC50 = 5.9 µM.19
This inhibitory effect was also observed in other
studies in which the INaL was pharmacologically
induced by the Anemonia sulcata toxin (ATX)-II.20,21
A later study showed that ranolazine blocked both
the peak Na+ current (INa) and the INaL with a
nine-fold selectivity for INaL vs. INa,22 and that this
blockade occurred at the same binding site where
other local anesthetics, such as lidocaine, interacts
with Na+ channels. Although the inhibitory effect of
ranolazine on Na+ current and especially on the INaL
may suggest an anti-arrhythmic effect, it could also
explain its mechanism as an anti-anginal drug on the
basis of preventing Na+ overload and the subsequent
increase in intracellular Ca2+.
Cytosolic Ca2+ overload is a key event in the injury
sustained during ischemia. It occurs due to activation
of the Na+/Ca2+ exchanger in the reverse mode as a
result of the increase in cytosolic Na+ which results
from impaired Na+/K+ ATPase pump activity, coupled
with an increased pH gradient between the intracellular and extracellular spaces and concomitant activation of the Na+/H+ exchanger.23 However, increased
cytosolic Na+ may also arise in part from activation
of the INaL by toxic ischemic metabolites24,25 and by
3
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reactive oxygen species that are generated during
reperfusion.26 Thus ranolazine, an inhibitor of INaL,
could reduce cytosolic Na+ during ischemia and subsequently reduce cytosolic Ca2+. Indeed, Song et al27
reported that ranolazine attenuated H2O2-induced
intracellular Na+ and Ca2+ overload in rabbit isolated
ventricular myocytes. We also showed that ranolazine reduced cytosolic Ca2+ in intact beating guinea
pig hearts undergoing global no flow ischemia, and
that this led to a decrease in mitochondrial Ca2+ overload and reactive oxygen species generation during
ischemia.28 These effects of ranolazine on mitochondria may underlie, in part, its cardio-protective effects
against ischemia. What remains unclear is the exact
mechanism by which ranolazine inhibits INaL.
Recent studies have focused on the pore-forming
subunit of the cardiac Na+ channel, Nav1.5, which is
the main ion channel that conducts Na+ in cardiac cells.
One interesting study showed mechano-sensitive properties for INa in isolated mouse cardiomyocytes.29 This
implies that the function of Nav1.5, among many other
described regulatory mechanisms, is also modulated
by the mechanical stretch of the membrane in which
it is embedded. However, and more importantly, the
novelty of the study came from the finding that ranolazine inhibited the mechano-sensitivity of Nav1.5 in
a dose dependent manner, and that this inhibition did
not require the established binding site. This study also
suggested that it is only the neutral form of ranolazine
that is capable of inhibiting the mechano-sensitivity
of Nav1.5, thus leading the authors to speculate that
ranolazine obtains access to the channel by partitioning within the lipid bilayer of the cell membrane.
Ranolazine inhibited the mechano-sensitivity of
Nav1.5 with an IC50 = 54 µM which is about 10-fold
higher than the therapeutic concentration. Nonetheless,
the authors suggest two reasons not to dismiss
these findings. First, the results were obtained in an
experimental model that does not mimic exactly the
true mechanical environment of the channels in situ
where other mechano-relevant elements likely mediate the mechano-sensitivity of the Nav1.5. Second,
ranolazine inhibits the mechano-sensitivity of Nav1.5
by partitioning into the bilayer hydrophobic core29 in
its neutral (effective) form. However, this partitioning increases with increasing temperatures and since
the experiments were conducted at room temperature, one can expect that the effective membrane
4

c oncentration of ranolazine will increase at the higher
physiological temperatures of the clinical setting.

Ranolazine and mitochondrial complex I

As mentioned earlier, the effect of ranolazine as a
metabolic modulator is probably related to increasing
the amount of the active dephosphorylated pyruvate
dehydrogenase. It is worth noting, however, that the
pyruvate dehydrogenase complex is exclusively intramitochondrial in mammalian tissues, which may
suggest that ranolazine has another site of action that
is intra-mitochondrial.8 Interestingly, Wyatt et al30
showed that ranolazine inhibited mitochondrial
respiration of NADH-linked substrates and that this
was due to inhibition of the mitochondrial electron
transport chain at the level of complex I. Furthermore,
the inhibition by ranolazine resembled that of rotenone
and amobarbital which are specific complex I blockers.
The significance of this is that inhibiting complex I
with amobarbital was protective against ischemic
injury as we and others have shown.31,32 We postulated
that inhibiting complex I during ischemia decreases
electron transfer from complex I to complex III,
thereby reduces electron leak, and superoxide (O2•−)
generation at complex III during late ischemia. So,
if ranolazine inhibits complex I in a manner similar
to that of rotenone and amobarbital, then it could
very well promote its anti-anginal effect in part by a
mitochondrial mediated mechanism, which involves
the reduction in reactive oxygen species generation
during ischemia and subsequently on reperfusion.
Indeed, ranolazine was shown to reduce reactive
oxygen species generation during ischemia.28 Furthermore, in a recent study Gadicherla et al showed
that in hearts exposed to global ischemia, the addition
of ranolazine on reperfusion improved mitochondrial
complex I activity, restored electron transfer through
Fe-S clusters of complex I, and preserved supercomplex assembly and cardiolipin integrity.33 However,
there was no evidence that these observations were
due to direct effects of ranolazine on complex I or
even on mitochondria. Therefore, it was concluded
that ranolazine indiscriminately reduced oxidative
damage to complex I and its supportive structures and
thus maintained optimal electron flow through complex I and reduced the tendency for electron leak and
the subsequent generation of O2•−. It is important to
mention that in the study by Wyatt et al30 ranolazine
Clinical Medicine Insights: Therapeutics 2013:5

Ranolazine and chronic stable angina

was shown to be a weak inhibitor of complex I when
compared with rotenone or amobarbital, especially
in energetically coupled mitochondria. However, in
uncoupled or broken mitochondria (sub-mitochondrial particles) ranolazine exerted a more potent
inhibitory effect on complex I. The authors suggested
that this inhibitory effect by ranolazine occurred
because of the lower membrane potential in uncoupled mitochondria coupled with a more acidic environment which favors greater protonation and uptake
of ranolazine, or that it is only the charged form of
ranolazine that is inhibitory. Nonetheless, regardless
of the conditions of energisation of the mitochondrial
inner membrane, the IC50 for inhibition of mitochondrial complex I by ranolazine was much higher than
its therapeutic concentrations.

Ranolazine modulates myofilaments
Ca2+ sensitivity

The general consensus so far is that ranolazine acts
as an anti-anginal and anti-ischemic drug primarily
by inhibiting INaL. In doing so, ranolazine prevents
cytosolic Na+ overload and the subsequent excess in
cytosolic Ca2+. The increase in cytosolic Ca2+ plays
a key role in ischemic injury by causing mitochondrial Ca2+ overload, which then triggers a cascade
of events that eventually leads to apoptosis/necrosis
and cell death.34,35 Increase in cytosolic Ca2+ may
induce damage by non-mitochondrial mechanisms
such as by activating Ca2+-dependent phospholipases
and proteases with the subsequent loss of structure
and function of the myocyte.36 Ca2+ also may induce
diastolic dysfunction which leads to a sustained contracture during diastole, an increase in myocardial O2
consumption and compression of intramural small
vessels, thus reducing nutritive blood flow to the ischemic territory.37 Interestingly ranolazine was found to
attenuate the diastolic dysfunction in several animal
studies38–43 and in human studies.44,45 While ranolazine may reduce diastolic dysfunction by inhibiting
INaL and the subsequent increase in cytosolic Ca2+, a
very recent study may shed some light on a different
mechanism for ranolazine.
In this study,46 the authors used a hypertensive
mouse model (deoxycorticosterone acetate [DOCA]salt) of diastolic dysfunction. It is important to mention that, in this study, no INaL was noted, nor were
there changes in Ca2+ cycling to indicate significant
Clinical Medicine Insights: Therapeutics 2013:5

alterations in Ca2+ handling in this form of diastolic
dysfunction. Yet ranolazine was effective in abating
this form of diastolic dysfunction. Myofilaments isolated from mice with diastolic dysfunction exhibited
increased maximal tension and sensitivity to Ca2+ as
well as a slowing of cross-bridge exit kinetics compared with sham mice, and these changes were normalized with ranolazine treatment. This suggested
that ranolazine improved diastolic function at the
cardiomyocyte level through the modulation of myofilament cross-bridge kinetics and sensitivity to Ca2+.
Additionally, ranolazine, acting directly on myofilaments, improved diastolic dysfunction in the DOCAsalt sensitive mice with the same concentrations used
clinically with no significant effects on hemodynamic
parameters. The results obtained from the DOCA-salt
sensitive mice may not be transferable to humans.
Nonetheless, the finding of this study may hint to a
new possible mechanism of ranolazine as an antianginal drug which deserves further exploration.

Clinical Studies

Several clinical trials have studied the effects of
ranolazine in patients with coronary heart disease.
Of these, three major trials focused on the role of
ranolazine in treating chronic stable angina and one
trial study focused on the role of ranolazine in treating acute coronary syndrome. A recent clinical trial
focused on the role of ranolazine in PCI, and one more
study assessed the cost of using ranolazine. There are
no further studies assessing the effects of ranolazine
on cardiovascular morbidity in patients with chronic
angina. These studies are summarized below.

MARISA trial

Before the MARISA (Monotherapy Assessment of
Ranolazine In Stable Angina) trial, clinical studies
focused on the immediate release formulation of ranolazine in combination with other anti-anginal drugs.
The MARISA trial was the first study to focus on the
sustained release formulation of ranolazine as a sole
treatment for angina. The purpose of the study was
to compare, in a dose dependent manner, the effects
of the sustained release formulation of ranolazine on
treadmill exercise performance and to provide longterm survival data in patients who completed the trial.10
In this study, 191 patients with documented CAD and
treated with anti-anginal drugs were enrolled. These
5
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CARISA trial

The purpose of the CARISA (Combination Assessment
of Ranolazine In Stable Angina) trial was to assess
the anti-anginal and anti-ischemic effects of ranolazine in symptomatic chronic angina patients with
severe CAD when combined with standard doses of a
typical anti-anginal drug, ie, atenolol, amlodipine, or
diltiazem.9 The efficacy end points included treadmill
exercise duration, time to angina, time to 1 mm STsegment depression at peak and trough, and the number of angina attacks and sublingual nitroglycerin uses
reported by the patients. In this study, 823 patients
were assigned randomly to receive placebo, 750 mg
ranolazine, or 1000 mg ranolazine twice daily for
6
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with ranolazine

C
Difference from placebo (sec)

patients had to discontinue their anti-anginal treatments
during the study except for sublingual nitroglycerin as
needed. Randomized patients received a double-blind
treatment with the sustained release formulation of
ranolazine at doses of 500, 1000, and 1500 mg or a
placebo, each administered twice daily for one week,
according to a four-period, balanced Latin Square
crossover design. At the end of each treatment period,
exercise treadmill tests were performed at 4 h (peak)
and later at 12 h (trough) after dosing. Compared
to placebo, treatment with ranolazine significantly
improved total exercise duration, time to angina, and
time to 1 mm ST-segment depression at both peak
and trough time points in a dose dependent manner
(Fig. 1). Increase in ranolazine plasma concentrations
was associated with an increase in mean exercise durations, but the increase in exercise duration appeared to
plateau at the higher ranolazine concentrations. Further
analysis showed that gender, age, diabetes, and prior
history of heart failure did not significantly modify
the treatment effects of ranolazine. Some patients
from the MARISA trial were still receiving ranolazine
at one year and two years after their first doses. Their
one-year and two-year survival rates on ranolazine
were 96.3% and 93.6%, respectively. The MARISA
study showed also that ranolazine was a safe drug
with side effects usually occurring at higher dosage.
Common side effects included constipation, nausea,
dizziness, and asthenia. Ranolazine also prolonged
the corrected QT (QTc) interval in a dose dependent
manner. In summary, the MARISA trial showed that
ranolazine is an effective and safe drug when used
alone as an anti-anginal treatment.
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1,500 mg b.i.d.

Figure 1. Summary of the effects of three doses of ranolazine on exercise
treadmill test parameters.
Notes: Values shown represent difference from placebo in seconds.
Data are mean ± standard error. *P , 0.05 in treatment with ranolazine
vs. placebo. b.i.d. = twice daily.

12 weeks in addition to receiving another typical
anti-anginal drug. The major finding was that ranolazine at the two doses significantly increased exercise
duration at both the trough and the peak concentrations (Fig. 2). More importantly, treatment with the
other anti-anginal drugs did not significantly modify
the response to ranolazine. Ranolazine decreased
the number of angina attacks and subsequently it
decreased nitroglycerin consumption (Fig. 3). Some
patients from the CARISA trial were still receiving
Clinical Medicine Insights: Therapeutics 2013:5
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Figure 2. Summary of the effects of two doses of ranolazine on exercise
treadmill test parameters.
Notes: Values shown represent difference from baseline values in
seconds. Placebo indicates treatment only with another anti-anginal
drug (atenolol 50 mg, amlodipine 5 mg, diltiazem 180 mg). Data are
mean ± standard error. *P , 0.05 in treatment with ranolazine vs.
placebo. b.i.d. = twice daily.

ranolazine at one year and two years after their first
doses. Their one-year and two-year survival rates on
ranolazine were 98.4% and 95.9%, respectively. As
in the MARISA trial, common side effects included
constipation, nausea, dizziness, and asthenia with
very few patients using 1000 mg ranolazine reporting
episodes of syncope. Ranolazine also caused small
Clinical Medicine Insights: Therapeutics 2013:5

2

*

1
0
Average
baseline

Placebo

Ranolazine
Ranolazine
750 mg b.i.d. 1,000 mg b.i.d.

+ another anti-anginal drug
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B

*

3

Figure 3. Summary of the effects of two doses of ranolazine on number
of angina attacks per week.
Notes: Placebo indicates treatment only with another anti-anginal
drug (atenolol 50 mg, amlodipine 5 mg, diltiazem 180 mg). Data are
mean ± standard error. *P , 0.05 in treatment with ranolazine vs.
placebo. b.i.d. = twice daily.

increases in QTc interval. In summary, the CARISA
trial showed that ranolazine can provide an additional
anti-anginal effect in patients treated with the classical anti-anginal drugs.

ERICA trial

Prior to the ERICA (Efficacy of Ranolazine In Chronic
Angina) trial, ranolazine was shown to be effective as
an anti-anginal treatment when used alone or in combination with other anti-anginal drugs at sub-maximal
dosage, but its efficacy when combined with a maximum recommended dosage of another conventional
anti-anginal treatment had not been investigated.
Therefore, the goal of the ERICA trial was to determine if ranolazine could reduce angina in patients with
persistent angina despite treatment with the maximal
recommended daily dosage of amlodipine.14 The efficacy of ranolazine was assessed by the weekly average frequency of angina episodes, the average weekly
nitroglycerin consumption rate, and the change from
baseline of the 5 dimensions of the Seattle Angina
Questionnaire (SAQ). Safety was assessed by evaluating reported adverse effects, hemodynamics, laboratory measures, and ECG. In this study, 565 patients
with $3 episodes of angina per week were receiving a maximum dosage of amlodipine at 10 mg/day.
In addition to amlodipine, patients were randomized
to also receive either 1000 mg ranolazine or placebo
twice daily for 6 weeks. Adding ranolazine reduced
the weekly rate of angina episodes (Fig. 4A), and it
reduced the average weekly rate of nitroglycerin consumption (Fig. 4B), but it improved only the angina
7
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A
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4
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2
1

Figure 4. Summary of the effects of ranolazine when added to a
maximum dose of amlodipine (10 mg) on the number of angina episodes
and nitroglycerin uses per week.
Notes: Data are mean ± standard error. *P , 0.05 in treatment with
ranolazine vs. placebo.

frequency dimension of the SAQ. The treatment effect
of ranolazine in different subgroups was numerically
similar to that in the population as a whole (Fig. 5),
however the study was not powered to test the treatment effects within subgroups. Ranolazine did not
induce any significant changes in heart rate or blood
pressure when compared to placebo. The adverse
effects occurred in 35.3% of amlodipine+placeboand 39.9% of amlodipine+ranolazine-treated patients
with women and patients older than 65 reporting
more adverse effects. In summary, the ERICA trial
demonstrated that ranolazine provided additional
anti-anginal benefit in patients who remained symptomatic despite being treated with the maximal dosage
of the Ca2+ channel blocker amlodipine.

MERLIN-TIMI 36 trial

The goal of the MERLIN (Metabolic Efficiency with
Ranolazine for Less Ischemia in Non-ST-Elevation
Acute Coronary Syndrome)-TIMI 36 trial was to
evaluate the efficacy and safety of ranolazine in the
short and long term in patients with acute coronary

4
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Amlodipine+ranolazine
Figure 5. Summary of the effects of ranolazine when added to a maximum dose of amlodipine (10 mg) on the number of angina episodes per
week in three subgroups.
Note: Data are mean ± standard error.
Abbreviation: LAN, long acting nitrate.

syndromes who were also receiving standard therapy.47
The primary efficacy end point was a composite of
cardiovascular death, myocardial infarction, or recurrent ischemia through the end of the study. The major
safety end points were assessed as death from any
cause and the incidence of symptomatic documented
arrhythmia. In this study, 6560 patients who were
receiving standard treatment for non-ST elevation
Clinical Medicine Insights: Therapeutics 2013:5
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acute coronary syndrome were also randomized to
additionally receive ranolazine or placebo. Ranolazine 200 mg (or matching placebo) was given first
intravenously within 1 h followed by slower intravenous infusion over the next 12–96 h. Then, ranolazine extended-release (or matching placebo) tablet
was given orally at a dose of 1000 mg twice daily for
the remainder of the study (up to 24 months with a
median of 348 days). Ranolazine did not reduce the
rate of cardiovascular death, myocardial infarction,
or recurrence of ischemia (ranolazine 21.8% vs. placebo 23.5%, P = 0.11), all considered as the primary
endpoints of the study. However, the effect of long
term treatment with ranolazine on angina was evident
as it reduced worsening angina (ranolazine 4.2% vs.
placebo 5.9%, P = 0.02). Moreover, an increase in
or addition of an anti-anginal drug was less frequent
(ranolazine 10.6% vs. placebo 13%, P = 0.003). There
was no significant heterogeneity in the effect of ranolazine on the primary endpoints across the major subgroups examined. Death from any cause did not differ
among patients treated with ranolazine compared with
patients treated with placebo. The incidence of symptomatic documented arrhythmias throughout the duration of the study was similar in patients treated with
ranolazine compared with placebo. However, the frequency of clinically significant arrhythmias observed
during Holter monitoring during the first 7 days was
lower in the ranolazine group vs. in the placebo group.
Adverse events (dizziness, nausea, constipation, syncope) were more frequent with ranolazine vs. placebo.
In summary, this study showed no significant benefit of
ranolazine compared with placebo with respect to the
primary efficacy endpoints. Also, ranolazine appeared
to be safe but with no difference from placebo with
respect to the safety endpoints.

Role of ranolazine during percutaneous
coronary intervention

Myocardial injury may occur in patients undergoing
PCI and this may lead to higher mortality. Therefore,
the goal of this study was to determine if pretreatment with ranolazine before PCI has any protective
role on periprocedural myocardial damage.48 The
primary endpoint was defined as the postprocedural
increase in creatine kinase-MB (CK-MB) $3 times
of the upper limit of normal indicating periprocedural
myocardial damage. Other cardiac markers such as
Clinical Medicine Insights: Therapeutics 2013:5

Troponin I and myoglobin levels were also measured.
In this study, 70 patients who fulfilled the inclusion
criteria and scheduled for elective PCI were included
and randomly divided into two groups, 35 patients
each. One group received placebo while the other
received ranolazine 1000 mg twice daily for 7 days
before the planned intervention. Ranolazine reduced
the periprocedural myocardial infarction (ranolazine
6% vs. placebo 22%, P = 0.041), which is the primary endpoint. Overall, there were fewer patients in
the ranolazine group compared to the placebo group
that showed increases above the upper limit of normal in CK-MB (ranolazine 23% vs. placebo 40%,
P = 0.01), troponin I (ranolazine 31% vs. placebo
48%, P = 0.011), and myoglobin (ranolazine 28%
vs. placebo 43%, P = 0.033). Further, ranolazine
reduced the incidence of death, myocardial infarction, or target-vessel revascularization at 30 days
after the procedure (ranolazine 9% vs. placebo 28%,
P = 0.03), but this was mainly influenced by the
periprocedural events because when periprocedural
infarctions were not counted there was no significant difference between the two groups (ranolazine
3% vs. placebo 6%, P = 1). In summary, this study
showed that pretreatment with ranolazine is effective
in decreasing the incidence of myocardial infarction
during PCI.

Costs and clinical outcome

Ranolazine per dose is more expensive than the other
traditional anti-anginal treatments. However, the focus
should be on total costs of care and not on the cost of
single treatment. Although some studies analyzed the
costs for treating angina, the study by Phelps et al49
was the first chronic angina medication-specific cost
comparative study. In this study, a large managed care
administrative claims database was analyzed to better understand the effect of ranolazine versus alternative anti-anginal drugs on health care use and total
costs of care. Specifically, the primary dependent
variables for this study were total costs of care and
rate of revascularization procedures and services. A
retrospective administrative claims-based analysis
from a large, geographically diverse US health insurance plan with 11.2 million commercial enrollees
was performed. First, patients who were identified
to have angina were selected. Then of these, only
patients who were prescribed a new anti-anginal drug
9
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(index event) that was not used within the previous
6 months (pre-index period) and continued using the
new treatment for 6 more months (post-index period)
were selected. This was to insure that only patients
who had uncontrolled angina or had side effects that
required their physician to alter their medication plan
were enrolled. After further exclusion, 4545 patients
were left for final analysis and were divided into
3 groups. Newly prescribed ranolazine, long acting
nitrates, or β-blockers/Ca2+ channel blockers. In the
6 months pre-index period, there were no significant
differences among all groups in total costs of care
and in the rates of revascularization. Interestingly,
even though ranolazine is more expensive per dose
than the other anti-anginal drugs, the unadjusted total
costs of care were lower for ranolazine than for the
other groups. This is likely a result of fewer hospitalizations in patients treated with ranolazine compared to the other non-ranolazine treated groups. The
ranolazine treated group also had significantly lower
revascularization rates in the 6 months post-index
period. Furthermore, a multivariate analysis was performed to control for differences in age, gender, and
presence of co-morbid conditions that can affect total
costs of care. But even then, the adjusted total costs
of care and revascularization rates were significantly
lower in the ranolazine treated group compared to
the other non-ranolazine treated groups. Therefore, it
was concluded that adding ranolazine to the therapy
of patients with poorly controlled angina could lead
to better outcome and lower costs compared with the

other alternatives. These finding are all summarized
in Table 2.

Safety

From all the 4 major clinical trials, ranolazine, at any
dose, did not induce clinically significant changes in
heart rate or blood pressure during rest or exercise.
Overall, the side effects event rate increased with higher
doses. The most common side effects of ranolazine
are dizziness, nausea, vomiting, constipation, headache, and asthenia. However, all these side effects are
mild to moderate in general, occur soon after using the
drug, and reverse promptly with reducing the dose or
discontinuation of treatment.50 The increase in adverse
events seen with the 1500 mg dose in MARISA is disproportionately larger than the increase in anti-anginal
efficacy; thus, the 1500 mg twice-daily dose is not recommended for clinical use. Postural hypotension and
syncope were observed in a small number of patients
taking $ 1000 mg ranolazine, most likely due to concomitant usage of other medications that are vasoactive or known to increase the plasma concentration of
ranolazine. However, this can be prevented by starting
ranolazine at a low dose (500 mg) and slowly increasing the dose as needed. Ranolazine may cause some
small changes in laboratory parameters such as an
increase in eosinophil count, an increase in creatinine,
a decrease in hematocrit, and a decrease in hemoglobin
A1C in diabetic patients. Ranolazine may prolong the
QTc interval in a dose dependent manner,9,10 therefore
it is recommended to avoid ranolazine in patients with

Table 2. A summary of the differences between ranolazine and the other traditional anti-anginal drugs in total costs of care
and rate of revascularization in the pre- and post-index period.
Ranolazine
(n = 881)

Nitrates
(n = 1788)

β blockers/Ca2+ channel
blockers (n = 1876)

Pre-index total cost $

19199

% pre-index revascularization

24.97

Unadjusted post-index total cost $

14781

% unadjusted post-index
revascularization
adjusted post-index total cost $

9.88

% adjusted post-index
revascularization

9.9

19841
(P = 0.603 vs. ranolazine)
26.51
(P = 0.394 vs. ranolazine)
17773
(P = 0.022 vs. ranolazine)
20.25
(P , 0.001 vs. ranolazine)
18166
(P , 0.001 vs. ranolazine)
20.4
(P , 0.001 vs. ranolazine)

18152
(P = 0.410 vs. ranolazine)
25.16
(P = 0.915 vs. ranolazine)
16785
(P = 0.120 vs. ranolazine)
15.51
(P , 0.001 vs. ranolazine)
17612
(P = 0.002 vs. ranolazine)
15.4
(P , 0.001 vs. ranolazine)

13961

Table assembled from Phelps et al. Clinical Therapeutics/Volume 34, Number 6, 2012.
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known long QTc and in patients taking drugs that may
prolong QTc.
Ranolazine is metabolized primarily in the liver by
the enzyme CYP3A4, therefore caution should be taken
in those who use other drugs that are known to interact
with this enzyme or in patients with hepatic dysfunction as this may cause accumulation of ranolazine.51
Furthermore, ranolazine is cleared mainly by the kidneys and so careful dose titration is recommended
in patients with mild to moderate renal impairment,
whereas it is completely contraindicated in patients
with severe renal impairment.52 Ranolazine is transported by P-glycoprotein7 and therefore it must be used
cautiously with drugs that inhibit P-glycoprotein such
as verapamil, as this may increase the absorption and
subsequently the plasma concentration of ranolazine.

Efficacy

Early on, ranolazine was manufactured in an immediate release form and several clinical trials tested its
efficacy for the treatment of chronic angina.11–13,53,54
These trials yielded results ranging from negative
effects to studies showing benefits of ranolazine as
an anti-anginal treatment. This range of effects likely
stems from the different dosages utilized. Eventually,
the immediate release form was replaced by the more
favorable extended (sustained) release form which is
now commercially available for treatment. The efficacy of this formulation was evaluated in the 4 large
clinical trials summarized above.9,10,14,47 MERLINTIMI 36 was the only study to assess the efficacy of
the extended formulation of ranolazine for treating
non-ST-elevation acute coronary syndrome and it
showed no benefit for ranolazine in this population.
However, the other three studies (MARISA, CARISA,
ERICA) demonstrated beneficial effects of ranolazine
in treating chronic angina. For example, ranolazine
alone (MARISA) increased the treadmill exercise
performance similar to that observed with other antianginal drugs.55,56 However, when ranolazine was
combined with other anti-anginal drugs in some trials (CARISA, ERICA), the beneficial effects of ranolazine seemed initially limited, ie, it reduced angina
episodes by nearly 1 per week, and it increased exercise duration by nearly 24–34 s at trough concentrations (MARISA) compared to placebo. Nonetheless,
one cannot underestimate these findings because a
small increase in exercise duration translates into the
Clinical Medicine Insights: Therapeutics 2013:5

ability of patients to carry on more daily living activities without being symptomatic. Therefore, and based
on these findings, it is safe to say that ranolazine is
recommended for the therapy of chronic angina as the
sole drug, or combined with other treatments.

Patient Preference

Based on federal published guidelines, pharmacological
management of chronic angina includes using short
acting nitrates for treating the episode of angina, and
then combined treatment with long acting nitrates,
β-blockers, and Ca2+ channel blockers.57 As an
alternative, ranolazine can also be used by itself or in
combination with other anti-anginal drugs. Each one
of these drugs has its share of side effects. Ranolazine,
however, is the exception in that it brings about its antianginal effects without significant clinical changes in
hemodynamics (blood pressure, heart rate). Therefore,
it may be well suited for patients with lower blood
pressures or heart rates in whom the addition or the
gradual increase in the dose of anti-anginal drugs with
important hemodynamic effects may not be tolerated.9
Moreover, ranolazine was shown to have antiarrhythmic58 and anti-diabetic effects.59 The latter is
of a particular interest since many patients who suffer
from chronic angina already have diabetes mellitus.
Ranolazine in fact was shown to reduce HbA1C in
patients with diabetes mellitus and to possibly mitigate
new hyperglycemia in patients at risk for diabetes
mellitus. These findings make ranolazine an attractive
anti-anginal treatment for patients with chronic angina
and impaired glucose metabolism.59
Ranolazine costs considerably more than the other
anti-anginal drugs per dose. However, and as discussed
earlier, a comprehensive retrospective claims analysis49 showed that adding ranolazine as a replacement
for another ineffective anti-anginal drug was associated with lower rates of prescription fills for short acting nitrates, reduced revascularization rates, and lower
total cost of care greater than with other anti-anginal
therapies (discussed above, see section Costs and Clinical Outcome). Therefore, the associated reductions
in non-pharmacy costs of care when using ranolazine
more than offset the higher prescription drug costs.49

Place in Therapy

The FDA approved the use of ranolazine as a
first line drug for the treatment of chronic angina.
11
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 owever, the European Society of Cardiology (ESC)
H
still recommends using ranolazine as an add-on therapy or as a substitution therapy when conventional
drugs are not tolerated.2 Recent guidelines from the
American College of Cardiology Foundation and
the American Heart Association (ACCF/AHA, etc)
also recommends using ranolazine in circumstances
in which other anti-anginal drugs are not adequately
effective or are not tolerated.60 Specifically, ranolazine can be used to relieve symptoms in patients
with stable ischemic heart disease in two cases: (1)
as a substitute for β-blockers if initial treatment with
β-blockers leads to unacceptable side effects or is
ineffective or if initial treatment with β-blockers is
contraindicated; (2) in combination with β-blockers
if the initial treatment with β-blockers is not successful. Ranolazine is available as extended-release tablets at 500 mg and 1000 mg, and a recommendation is
to start ranolazine at 500 mg twice daily and increase
to 1000 mg twice daily, as needed, based on clinical symptoms. The MERLIN-TIMI 36 trial showed
no benefit of ranolazine in treating acute coronary
syndrome; therefore ranolazine is not approved for
treating these conditions. Clinical trials did not show
significant differences in the efficacy of ranolazine
between younger and older patients. However, older
patients may have a greater frequency of decreased
hepatic or renal function and therefore it is recommended to start ranolazine at the lowest dosing range
in this population. Ranolazine should not be used in
patients with cirrhosis, severe renal insufficiency,
preexisting long QTc, or in patients using drugs that
are known to prolong QTc or inhibit CYP3A4.

Conclusions

Coronary heart disease remains a global malady
despite the advancement in its management. Chronic
angina is one manifestation of CAD. Traditional
anti-anginal therapy includes drugs that decrease
O2 demand and increase blood flow. Ranolazine,
however, belongs to a different class of anti-anginal
drugs. It antagonizes the disturbance in ion homeostasis, specifically Na+ and subsequently Ca2+ that may
occur during ischemia by inhibiting the INaL. Other
possible mechanisms including its direct effect on
cardiac myofilaments, or indirectly preserving mitochondrial complex I, may in part mediate its effects
as an anti-anginal drug. Although ranolazine is more
12

expensive than other traditional treatments per dose,
it actually cuts the non-pharmacy costs of care in the
long run. However, it remains important to compare
total costs of care of ranolazine with the other antianginal drugs when ranolazine is used as a new, first
line, anti-anginal drug and not only as an alternative therapy when the other treatments fail to control
angina. Clinical trials showed ranolazine to lack many
of the hemodynamic side effects observed with the
other anti-anginal drugs, and more importantly to be
an effective anti-anginal treatment when used alone
or in combination with other conventional treatments.
Yet, a direct comparison between ranolazine and the
other conventional anti-anginal drugs (β-blockers,
Ca2+ channel blockers, nitrates) is warranted before
ranolazine can seriously be recommended as a first
line therapy for chronic angina.
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